Relationship of TSH levels with cardiometabolic risk factors in US youth aged 12-18 years and population-based reference percentiles for thyroid function tests.

Xinlei Chen, MS¹, Shuliang Deng, MS¹, Cecilia Sena, BA², Chuhan Zhou, MS³, Vidhu V. Thaker, MD²

¹Department of Biostatistics, Columbia Mailman School of Public Health, New York, NY 10032

²Department of Pediatrics, Columbia University Medical Center, New York, NY 10032

³ Columbia University Institute of Human Nutrition, New York, NY 10032

Abstract

Context: Thyroid hormones play an important role in the metabolic homeostasis of the body and have been associated with cardiometabolic risk.

Objective: To examine the association of cardiometabolic risk factors (CMRF) with TSH levels in youth at population level in the US.

Design & Setting: Cross-sectional study of youth aged 12-18 years without known thyroid abnormalities from National Health and Nutrition Examination Survey 1999-2012. Subclinical hypothyroidism (SH) was defined as TSH levels 4.5-10 mIU/L. Assessed CMRF included abdominal obesity (waist circumference > 90th percentile), hypertriglyceridemia (TG $\geq$ 130 mg/dL), low HDL cholesterol (HDL-C < 40 mg/dL), elevated blood pressure (SBP and DBP $\geq$ 90th percentile), hyperglycemia (FBG $\geq$ 100 mg/dL, or known diabetes), insulin resistance (HOMA-IR > 3.16) and elevated alanine transferase (ALT $\geq$ 50 U/L for boys and $\geq$ 44 U/L for girls). Age and sex- specific percentiles for thyroid parameters were calculated for youth with normal weight.

Results: In this cohort of youth (51.3% male), 31.2% had overweight/obesity. The prevalence of SH was 2.0 % (95% CI 1.2-3.1). The median TSH levels were higher in youth with overweight/obesity ($p < .001$). Adjusting for age, sex, race/ethnicity and level of obesity, youth with TSH in the 4th quantile had higher odds of abdominal obesity (OR 2.53 [1.43-4.46], $p = .002$), higher HOMA-IR (OR 2.82 [1.42-5.57], $p = .003$) and ≥ 2 CMRF (OR 2.20 [1.23-3.95], $p = .009$).

Conclusions: The prevalence of SH is low in US youth. The higher odds of insulin resistance and CMRF in youth with TSH levels > 75th percentile requires further study.

Introduction

Thyroid hormones play an important role in normal growth and development as well as regulating metabolism, thermogenesis and cardiovascular function (1). Many of the metabolic activities regulated by thyroid hormones are related to the anabolism and/or catabolism of macromolecules that affect energy homeostasis, and thyroid hormones triiodothyronine (T3) and thyroxine (T4) have direct effects on both cholesterol and fatty acid synthesis and metabolism (2,3). The feedback loop of thyroid function is regulated by the thyroid stimulating hormone (TSH) secreted from the anterior pituitary in response to the circulating thyroid hormone(s). TSH levels in the blood are the most sensitive markers of optimal thyroid function and mild elevation of TSH, called subclinical hypothyroidism (SH, TSH 4.5-10 mIU/L), has been considered the earliest manifestation of thyroid dysfunction. In adults, SH has been associated with adverse cardiovascular outcomes, such as carotid intima thickness (4,5), coronary heart disease (6), heart failure (7), stroke (8), non-alcoholic fatty liver disease (9), and the role of thyroid replacement therapy is being debated (10,11).

Cohort studies in children and adolescents have found an association between elevated TSH levels or SH and obesity (12-17). An association has also been demonstrated between SH and cardiometabolic risk factors (CMRF), such as hypercholesterolemia (18,19), carotid intima thickness (19) and glucose dysmetabolism (20-22). Whether these associations are a result of the insulin resistance seen with obesity or are independently associated with TSH remains to be established. There is sparsity of such studies from population-based cohorts.

The objective of this study was to assess the relationship between TSH levels and CMRF namely abdominal obesity, dyslipidemia, glucose intolerance, elevated blood pressure, insulin resistance and elevated alanine transferase (23) in a nationally representative sample of children and adolescents from the US from the National Health and Nutrition Examination Survey (NHANES). Additionally, we aimed to identify the reference percentiles for measures of thyroid function by age and gender in children with BMI percentiles between 5-85.

Material and Methods

Study population

The data for this study was obtained from combining five 2-year cycles of NHANES where thyroid function tests were measured (1999-2000; 2001-2002 and 2007-2008 through 2011-2012). NHANES is a cross-sectional, multi-stage complex nationally representative survey that uses interview, physical examination and

laboratory data to assess the health and nutritional status of the non-institutionalized civilian population in the US(24).

Study cohort

Subjects for the study are youth between the ages of 12-18 years at the time of examination. Data pertinent to the thyroid function, lipid levels, liver enzymes, measures of glucose homeostasis in fasting samples, anthropometric and demographic measures were obtained. Subjects with history of thyroid disease or those on thyroid supplements or drugs that influence thyroid function, such as steroids, lithium, amiodarone, or beta blockers were excluded. Additionally, subjects with clinical hypothyroidism, hyperthyroidism, the presence of anti-thyroid antibodies (anti-thyroidperoxidase [TPO] or anti-thyroglobulin [TG]) and those with abnormal creatinine were excluded from the analysis. The interview data contains information on race/ethnicity that was classified as non-Hispanic white (NHW), non-Hispanic black (NHB), Hispanic or other. The average response rate for the study cohort was 80% (range 75 – 85). The National Center for Health Statistics Institutional Review Board oversaw the written, informed consent for emancipated minors and parents and guardians for minors for data collection.

Anthropometric measurement

NHANES survey instruments and protocols have been established and ongoing in 2-year cycles since 1999 (25). Briefly, anthropometric measures include weight measured to the nearest 0.1kg using a digital weight scale with participants wearing the standard mobile examination center (MEC) examination gown. Standing height was measured to the nearest 0.1cm using a stadiometer with a fixed vertical backboard and an adjustable head piece. Body mass index (BMI) was calculated as weight (kg)/height (m) squared. Subjects with BMI between 5-84 percentile were considered without obesity, 85-94 percentile overweight and $\geq 95^{\text{th}}$ percentile with obesity (26). Waist circumference was measured in the horizontal plane to the nearest 0.1cm at the junction between the uppermost lateral border of the right ilium and the midaxillary line which extends from the armpit down the side of the torso. Blood pressure was measured 3 times and the average was used.

Biochemistry assessment

TSH was measured with a two-site immunoassay and the total T4 was measured with a competitive binding immunoassay (27-31) (eTable 1). The Total T4 levels for 2011-2012 cycle were adjusted to align with the measurements from the prior years for instrument change (31). TG antibody and TPO antibody

were measured using a sequential two-step immunoenzymatic "sandwich" assay (28-31). Triglycerides were measured enzymatically in serum or plasma using a series of coupled reactions in which triglycerides are hydrolyzed to produce glycerol. High density cholesterol (HDL-C) was measured by heparin-manganese precipitation or direct immunoassay method. The fasting plasma glucose and insulin levels were forward calibrated to the methodology used in 2011-12 (32-36). Alanine Aminotransferase (ALT) was measured by the catalytic action that causes the interconversion of amino acids and α -ketoacids by transfer of amino groups.

Cardiometabolic risk factors (CMRF)

We used the organizational framework offered by metabolic syndrome (MetS) to assess the CMRF in children and adolescents (23). For this study, the criteria defined by the International Diabetes Federation (37) were updated for hypertriglyceridemia and elevated blood pressure according to current guidelines as follows: a) abdominal obesity (waist circumference > 90th percentile for 10-16 years and/or ≥ 94 cm in males and ≥ 80 cm for females); b) hypertriglyceridemia (TG ≥ 130 mg/dL) (38); c) low high density cholesterol (HDL-C < 40 mg/dL); d) elevated blood pressure (Systolic and Diastolic BP $\geq 90^{\text{th}}$ percentile) (39); d) hyperglycemia (FBG ≥ 100 mg/dL, or reported diagnosis of diabetes). Two additional measures of metabolic risk used were insulin resistance measured by homeostatic model for insulin resistance (HOMA-IR = fasting insulin (microU/L) x fasting glucose (mmol/L) /22.5) (40) with > 3.16 considered high (41) and ALT levels as a measure for hepatic steatosis (≥ 50 U/L for boys and ≥ 44 U/L for girls) (42).

Data analysis

BMI and waist circumference were transformed into age and sex appropriate percentiles and z-score respectively using the CDC 2000 growth charts (43). The thyroid related variables were examined by probability density estimation to assess the shape of distribution. The summary of the distribution is presented as median with standard deviation for continuous variables or percentage for categorical variables. The characteristics of participants were compared using complex survey design adjusted differences in the median.

TSH quantiles were generated using quantile regression adjusting for age and sex to account for the absence of the pubertal status in the NHANES dataset. The 4th quantile was considered to be relevant for cardiometabolic risk. After ensuring absence of temporal trends between the survey cycles, the 5-survey cycles were combined for analysis and 10-year survey weights were constructed by rescaling the NHANES survey weights so that the sum of the weights matches the survey population at the midpoint of that period(44).

Univariate and multivariable analysis using complex survey-based generalized linear models with a logarithmic link was used to assess the odds of the CMRF with TSH quantiles while adjusting for the age, gender, race/ethnicity and level of obesity. A binary classification of TSH using the definition of SH (4.5 mIU/L with normal free T4 levels) was used to assess the association of the risks with SH (10,45). Survey based goodness of fit tests were done to test the model fit. Interaction between the predictors were tested using design-adjusted Wald test and likelihood ratio tests.

We imputed the missing data of TSH by multivariate imputation by chained equations using predictive mean matching to ascertain the percentiles of TSH. The imputation was verified by random verification of the complete dataset with similar methods. Sensitivity analysis for the results was performed using the complete cases. The terms with p-value < 0.05 were considered statistically significant and 95% confidence interval (CI) was calculated. Age- and sex-specific percentiles of TSH levels and other thyroid parameters among subjects with BMI between 5-85th percentiles were calculated using the imputed dataset by Generalized Additive Models for Location Scale and Shape (GAMLSS) package using different Box-Cox transformation distribution family and the best fitted model was determined by the Akaike Information Criterion.

Statistical analyses were performed in R v3.5.1 using tidyverse, survey, quantreg, mice, gamlss packages and STATA (StataCorp 2019. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC).

Results

Characteristics of study subjects

The final study cohort was representative of 15.4 million youth between the ages of 12-18 years of age (51.3% boys, 95% CI 49.2-53.4%), of which 31.2% (95% CI 28.5-38.1%) had BMI $\geq$ 85th percentile. Participants were excluded if TSH $\geq$ 10 mIU/L (n = 5), total T4 > 13.2 ug/dL (n= 10), positive for antithyroid antibodies (n = 202), or on medications affecting thyroid function (n = 20). The characteristics of the study subjects are shown in Table 1 grouped by BMI percentile. The distribution of age and gender was similar between the two groups. As has been shown before, the prevalence of obesity was higher in Hispanic and Non-Hispanic Black youth(46) . The CMRF were higher in the group with overweight/obesity by BMI percentile. The TSH levels were significantly different between the two groups, while the total and free T4 and total T3 levels were not. In the subgroup analysis by gender, the TSH levels were similar in both, but other thyroid parameters were statistically different. In the CMRF, waist circumference z-scores were lower in girls with obesity. HDL-C levels

were higher and ALT levels were lower in the girls, and HOMA-IR was similar in either gender with obesity (eTable 2). We evaluated the temporal trends in TSH, Total T4 and Total T3 by NHANES cycles and found no differences (eFigure 1). The distribution of the CMRF by the TSH quantiles and gender is shown in eTable 3.

Cardiometabolic risk factors by TSH levels

The CMRF were significantly higher in the group with overweight/obesity by BMI percentile, as were the TSH levels (Table 1). There was a positive correlation between TSH levels and BMI-z score ($r = 0.1$, $p < .001$), waist circumference ($r=0.2$, $p<.001$), HOMA-IR ($r= 0.1$, $p <.001$), and triglycerides ($r=0.1$, $p <.001$). A greater number of subjects with overweight and obesity were seen in the higher age and sex adjusted quantiles (Fig. 1). In the regression analyses weighted by the 10-year constructed weights, the 4th quantile of TSH was associated with increased odds of abdominal obesity, hypertriglyceridemia, elevated blood pressure, abnormal HOMA-IR, abnormal ALT levels and multiple risk factors as compared to the 1st quantile (Table 2, Model 1). This association continued to have statistical significance while controlling for age, gender and race/ethnicity (Model 2). When controlling for level of obesity in addition to age, gender and race/ethnicity, the 4th quantile for TSH was significantly associated with abdominal obesity, abnormal HOMA-IR and ≥ 2 CMRF (Model 3). Two percent (95% CI 1.2-3.1) subjects had SH by the conventional definition, with no differences between the two BMI categories. No association was seen between the presence of SH and any of the CMRF. No statistically significant interactions were identified between the predictors using design-based tests.

Age- and sex-specific percentile of TSH levels among normal weight subjects

Generalized Additive Models were used to derive the age- and sex-specific percentiles of thyroid parameters based on the values for the subjects with BMI between 5-85th percentile (Table 3). TSH levels decreased with increasing age and were consistently lower in girls compared to the boys in each age category. On the other hand, the total T4 levels increased with age and were higher in girls compared to the boys. The total T3 levels decreased with increasing age and were higher in girls. The levels of the free T4 as well as free T3 remained remarkably consistent across ages. The percentile curves can be seen in eFigure 2.

Discussion

This is the first study to comprehensively examine the association of TSH levels with CMRF in children from a nationally representative non-institutionalized population in the United States comprising of 5 NHANES cycles over 10 years. The prevalence of SH was low (2.0%, 95% CI 1.2-3.1) in this study with no differences in

children with normal BMI or those with overweight and obesity. This is remarkably different from the report of SH in 14.2% children in the Korean National Health and Nutrition Examination Surveys reported by Lee *et al* with statistically significant higher proportion in children with obesity (47). Asians are known to have higher cardiometabolic risk compared to other ethnicities at comparable age and sex-adjusted BMI (48-51) and the higher prevalence of SH may reflect similar racial/ethnic differences. Further, it is possible that the higher level of SH may be associated with the presence of anti-thyroid antibodies as no assays were reported for these in their study.

SH is frequently reported in children with overweight and obesity (12,17,18) and one study has shown its resolution with treatment achieved by medical or surgical means (52). The elevated leptin levels seen in obesity and the homeostatic mechanism for preserving body weight are thought to be the mechanisms underlying the elevated TSH levels seen with obesity (53-55). In this study, we showed an association of higher TSH levels with abdominal obesity and insulin resistance after controlling for covariates such as age, gender, race/ethnicity and level of obesity. Animal and human studies have identified a complex relationship of thyrotropin, thyroid hormones and glucose metabolism (56). Whether such relationships are mediated by the direct effects of TSH and thyroid hormones on skeletal muscle and adipose tissue or via hepatic metabolism or mitochondrial oxidation remains to be identified (56,57). Euglycemic-hyperinsulinemic clamp studies in humans have demonstrated decreased insulin-mediated glucose disposal in individuals with hypothyroidism (58) that reverted with treatment (58,59). Whether the reduced peripheral insulin sensitivity in hypothyroid state is caused by the reduction of blood flow to the skeletal muscle and adipose tissue as seen in a study that measured the differences in the arteriovenous sampling in hypothyroid individuals compared to normal controls (60) or other mechanisms such as an increase in glucose uptake by skeletal muscle and adipose tissue demonstrated in an individual with defect in insulin receptor treated with liothyronine (61) remains to be elucidated. In a longitudinal study of health check-up program, Jun *et al* have shown that the risk of incident Type 2 diabetes was significantly increased with each 1 mIU/mL increment in TSH after adjusting for confounding factors and that individuals in the highest tertile of TSH change were at greater risk (62,63). The findings from our study suggest that the association between the higher TSH levels and insulin resistance begins in early adolescence and may need long-term monitoring.

Circulating TSH is an important homeostatic hormone required for maintaining the body milieu and linear association of risk factors with TSH levels is unlikely. The association of cardiometabolic risks with the higher quantile may suggest that perhaps, the currently accepted upper range of normal levels of TSH requires modification. This issue has previously been debated in adult population with the report of mean TSH of 1.50 mIU/L (95% CI 1.46-1.54) in 13,344 people evaluated in NHANES III (64). In a subsequent study, it was reported that the prevalence of TPO antibody was higher in the individuals with TSH levels > 2 mIU/L, especially in those of older age. Therefore, the tail of the distribution with the higher TSH levels may represent occult thyroid dysfunction and an accurate population reference range remains an open question (65,66). The American Thyroid Association currently maintains that in children levothyroxine replacement therapy may be initiated with TSH > 10 mIU/L with signs/symptoms consistent with thyroid disease. It is also noted that if treatment is initiated, the goal of therapy is to maintain the TSH levels in the lower half of reference range, optimally between 0.5-2.0 mIU/L (67). These guidelines leave the range between 2-10 mIU/L without specific guidance, frequently resulting in referral to pediatric endocrinology providers, with disproportionately higher referrals of children with obesity. The debate on whether or not children with SH with or without obesity should be treated continues (68). Whether the higher odds of cardiometabolic risk in the 4th quantile translates into therapeutic relevance can only be determined by longitudinal studies in future.

To provide guidance to the clinicians caring for children, we have calculated the percentiles for the thyroid hormones in youth between 12-18 years of age with BMI between 5-85th percentiles without TPO or TG antibody at the time of assessment. The TSH levels decreased with increasing age from 12 to 18 years, while the Total T4 levels increased and the free T4 levels remained stable across the ages. In a study of Danish children, similar trends were seen, although the absolute levels were higher perhaps reflecting differences in assay or differences between populations (69). The 4th quantile of TSH most closely aligns with the 75th percentile of TSH. Future studies should address the optimal cut-off for TSH levels.

There are several limitations of this study. First, we have combined the results from assays used to assess thyroid function parameters over 5 NHANES cycles over 10 non-contiguous years. While the distribution of the measured hormonal levels overlaps in these 5 cycles, the possibility of differences across platforms remains. The NHANES survey does not include assessment for puberty. We used quantiles adjusted for age and sex to account for this lack of information, that may or may not capture the influence of puberty on

thyroid function. We reconstructed the weights from the 5 different NHANES cycles in this analysis. While this estimation is according to the prevalent guidelines from CDC, it is possible that these reconstructed weights may not apply to the population at large at a given time. The cardiometabolic risk factors were ascertained at the same time as the measurement of TSH, hence no inference can be drawn about causation. Finally, the study cohort was ascertained nearly a decade ago. Although we observed no temporal differences in the measurements from 1999- 2012, it is possible that the more recent trends may be different.

Notwithstanding these limitations, we believe that this study provides an important reference for clinicians in practice, both for the reference ranges provided as well as the association of CMRF with the highest quantile of TSH levels. Future longitudinal studies are needed to estimate if these CMRFs translate into adverse cardiometabolic outcomes and whether intervention with thyroid replacement therapy to maintain the TSH levels within a certain percentile is warranted.

Acknowledgements: The authors gratefully acknowledge the critical review of the manuscript by Bat-Sheva Levine, MD, MPH from Boston Children's Hospital and Stavroula Osganian, MD, ScD from National Institutes of Health (NIH). We are grateful to Qixuan Chen, PhD, from the Mailman School of Public Health at Columbia University for biostatistical consultation. We thank Morten Asp Vonsild Lund, MD PhD from the Department of Biomedical Sciences at University of Copenhagen for sharing their R code. This publication was supported in part by the National Institute for Diabetes and Digestive and Kidney Diseases, NIH, through Grant Number K23 DK110539 and the National Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. Brent GA. Mechanisms of thyroid hormone action. *J Clin Invest*. 2012;122(9):3035-3043.
2. Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. *Med Clin North Am*. 2012;96(2):269-281.
3. Duntas LH. Thyroid disease and lipids. *Thyroid*. 2002;12(4):287-293.
4. Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis. *Atherosclerosis*. 2013;227(1):18-25.
5. Aziz M, Kandimalla Y, Machavarapu A, Saxena A, Das S, Younus A, Nguyen M, Malik R, Anugula D, Latif MA, Humayun C, Khan IM, Adus A, Rasool A, Veledar E, Nasir K. Effect of Thyroxin Treatment on Carotid Intima-Media Thickness (CIMT) Reduction in Patients with Subclinical Hypothyroidism (SCH): a Meta-Analysis of Clinical Trials. *J Atheroscler Thromb*. 2017;24(7):643-659.
6. Collet TH, Bauer DC, Cappola AR, Asvold BO, Weiler S, Vittinghoff E, Gussekloo J, Bremner A, den Elzen WP, Maciel RM, Vanderpump MP, Cornuz J, Dorr M, Wallaschofski H, Newman AB, Sgarbi JA, Razvi S, Volzke H, Walsh JP, Aujesky D, Rodondi N. Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. *J Clin Endocrinol Metab*. 2014;99(9):3353-3362.
7. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. *Circulation*. 2012;126(9):1040-1049.
8. Chaker L, Baumgartner C, den Elzen WP, Ikram MA, Blum MR, Collet TH, Bakker SJ, Dehghan A, Drechsler C, Luben RN, Hofman A, Portegies ML, Medici M, Iervasi G, Stott DJ, Ford I, Bremner A, Wanner C, Ferrucci L, Newman AB, Dullaart RP, Sgarbi JA, Ceresini G, Maciel RM, Westendorp RG, Jukema JW, Imaizumi M, Franklyn JA, Bauer DC, Walsh JP, Razvi S, Khaw KT, Cappola AR, Volzke H, Franco OH, Gussekloo J, Rodondi N, Peeters RP. Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis. *J Clin Endocrinol Metab*. 2015;100(6):2181-2191.
9. Mantovani A, Nascimbeni F, Lonardo A, Zoppini G, Bonora E, Mantzoros CS, Targher G. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Thyroid*. 2018;28(10):1270-1284.
10. Biondi B, Cappola AR, Cooper DS. Subclinical Hypothyroidism: A Review. *Jama*. 2019;322(2):153-160.
11. Taylor P, Bianco AC. Urgent need for further research in subclinical hypothyroidism. *Nat Rev Endocrinol*. 2019;15(9):503-504.
12. Krause AJ, Cines B, Pogrebnik E, Sherafat-Kazemzadeh R, Demidowich AP, Galescu OA, Brady SM, Reynolds JC, Hubbard VS, Yanovski JA. Associations between adiposity and indicators of thyroid status in children and adolescents. *Pediatr Obes*. 2016;11(6):551-558.
13. Reinehr T. Thyroid function in the nutritionally obese child and adolescent. *Curr Opin Pediatr*. 2011;23(4):415-420.
14. Giannakopoulos A, Lazopoulou N, Pervanidou P, Kanaka-Gantenbein C. The Impact of Adiposity and Puberty on Thyroid Function in Children and Adolescents. *Child Obes*. 2019;15(6):411-415.
15. Aypak C, Turedi O, Yuce A, Gorpelioglu S. Thyroid-stimulating hormone (TSH) level in nutritionally obese children and metabolic co-morbidity. *J Pediatr Endocrinol Metab*. 2013;26(7-8):703-708.
16. Ayala-Moreno MR, Guerrero-Hernandez J, Vergara-Castaneda A, Salazar-Aceves G, Cruz-Mercado DE. Thyroid function in pediatric population with different nutritional status. *Boletín medico del Hospital Infantil de Mexico*. 2018;75(5):279-286.
17. Dahl M, Ohrt JD, Fonvig CE, Kloppenborg JT, Pedersen O, Hansen T, Holm JC. Subclinical Hypothyroidism in Danish Lean and Obese Children and Adolescents. *J Clin Res Pediatr Endocrinol*. 2017;9(1):8-16.
18. Iqbal AM, Lteif AN, Kumar S. Association between mild hyperthyrotropinemia and hypercholesterolemia in children with severe obesity. *J Pediatr Endocrinol Metab*. 2019;32(6):561-568.
19. Ruminska M, Witkowska-Sedek E, Majcher A, Brzewski M, Krawczyk M, Pyrzak B. Serum TSH level in obese children and its correlations with atherogenic lipid indicators and carotid intima media thickness. *Journal of ultrasonography*. 2018;18(75):296-301.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

20. Lundback V, Ekblom K, Hagman E, Dahlman I, Marcus C. Thyroid-Stimulating Hormone, Degree of Obesity, and Metabolic Risk Markers in a Cohort of Swedish Children with Obesity. *Horm Res Paediatr*. 2017;88(2):140-146.
21. Ma CG, Shim YS. Association of Thyroid-Stimulating Hormone and Thyroid Hormones with Cardiometabolic Risk Factors in Euthyroid Children and Adolescents Aged 10-18 Years: A Population-Based Study. *Sci Rep*. 2019;9(1):15476.
22. Ozer S, Butun I, Sonmezgoz E, Yilmaz R, Demir O. Relationships among thyroid hormones and obesity severity, metabolic syndrome and its components in Turkish children with obesity. *Nutr Hosp*. 2015;32(2):645-651.
23. Magge SN, Goodman E, Armstrong SC. The Metabolic Syndrome in Children and Adolescents: Shifting the Focus to Cardiometabolic Risk Factor Clustering. *Pediatrics*. 2017;140(2).
24. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data, U.S. Department of Health and Human Services, 2007-2011. Vol 2019. Hyattsville, MD.
25. Centers for Disease Control and Prevention. About the National Health and Nutrition Examination Survey. Vol 2020.
26. Barlow SE, Expert C. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. *Pediatrics*. 2007;120 Suppl 4:S164-192.
27. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 1999-2000 data documentation, codebook and frequencies. LAB18T4. Vol 2020.
28. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2001-2002 data documentation, codebook and frequencies. SSNH4THY. Vol 2020.
29. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2007-2008 data documentation, codebook and frequencies. THYROID_E. Vol 2020.
30. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2009-2010 data documentation, codebook and frequencies. THYROID_F. Vol 2020.
31. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2011-2012 data documentation, codebook and frequencies. THYROID_G. Vol 2020.
32. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2011-2012 data documentation, codebook and frequencies. GLU_G. Vol 2020.
33. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2009-2010 data documentation, codebook and frequencies. GLU_F. Vol 2020.
34. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2007-2008 data documentation, codebook and frequencies. GLU_E. Vol 2020.
35. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 2001-2002 data documentation, codebook and frequencies. L10_2_B. Vol 2020.
36. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: 1999-2000 data documentation, codebook and frequencies. LAB10AM. Vol 2020.
37. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S. The metabolic syndrome in children and adolescents - an IDF consensus report. *Pediatr Diabetes*. 2007;8(5):299-306.
38. Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, Adolescents, National Heart L, Blood I. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128 Suppl 5:S213-256.
39. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics*. 2017;140(3).
40. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28(7):412-419.
41. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. *Pediatrics*. 2005;115(4):e500-503.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

42. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). *J Pediatr Gastroenterol Nutr*. 2017;64(2):319-334.
43. Centers for Disease Control and Prevention (CDC): A SAS Program for the 2000 CDC Growth Charts (ages 0 to < 20 years). Vol 2018: Centers for Disease Control; 2016.
44. Centers for Disease Control (CDC). National Health and Nutrition Examination Survey. Tutorials Module 3: Weighting. Vol 2020.
45. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *Jama*. 2004;291(2):228-238.
46. Ogden CL, Fryar CD, Martin CB, Freedman DS, Carroll MD, Gu Q, Hales CM. Trends in Obesity Prevalence by Race and Hispanic Origin-1999-2000 to 2017-2018. *JAMA*. 2020.
47. Lee MK, Kim YM, Sohn SY, Lee JH, Won YJ, Kim SH. Evaluation of the relationship of subclinical hypothyroidism with metabolic syndrome and its components in adolescents: a population-based study. *Endocrine*. 2019.
48. Expert Consultation W. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet (London, England)*. 2004;363(9403):157-163.
49. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. *Am J Clin Nutr*. 2004;79(1):31-39.
50. Razak F, Anand SS, Shannon H, Vuksan V, Davis B, Jacobs R, Teo KK, McQueen M, Yusuf S. Defining obesity cut points in a multiethnic population. *Circulation*. 2007;115(16):2111-2118.
51. Shai I, Jiang R, Manson JE, Stampfer MJ, Willett WC, Colditz GA, Hu FB. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. *Diabetes Care*. 2006;29(7):1585-1590.
52. Licenziati MR, Valerio G, Vetrani I, De Maria G, Liotta F, Radetti G. Altered Thyroid Function and Structure in Children and Adolescents Who Are Overweight and Obese: Reversal After Weight Loss. *J Clin Endocrinol Metab*. 2019;104(7):2757-2765.
53. Fontenelle LC, Feitosa MM, Severo JS, Freitas TE, Morais JB, Torres-Leal FL, Henriques GS, do Nascimento Marreiro D. Thyroid Function in Human Obesity: Underlying Mechanisms. *Horm Metab Res*. 2016;48(12):787-794.
54. Ghamari-Langroudi M, Vella KR, Srisai D, Sugrue ML, Hollenberg AN, Cone RD. Regulation of thyrotropin-releasing hormone-expressing neurons in paraventricular nucleus of the hypothalamus by signals of adiposity. *Mol Endocrinol*. 2010;24(12):2366-2381.
55. Harris M, Aschkenasi C, Elias CF, Chandrankunnel A, Nillni EA, Bjorbaek C, Elmquist JK, Flier JS, Hollenberg AN. Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. *J Clin Invest*. 2001;107(1):111-120.
56. Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction? *J Thyroid Res*. 2011;2011:152850.
57. Crunkhorn S, Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? *Thyroid*. 2008;18(2):227-237.
58. Rochon C, Tauveron I, Dejoux C, Benoit P, Capitan P, Fabricio A, Berry C, Champredon C, Thieblot P, Grizard J. Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism. *Clin Sci (Lond)*. 2003;104(1):7-15.
59. Stanická S, Vondra K, Pelikánová T, Vlcek P, Hill M, Zamrazil V. Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. *Clin Chem Lab Med*. 2005;43(7):715-720.
60. Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, Koukkou E, Tzanela M, Thalassinou N, Raptis SA. Insulin action in adipose tissue and muscle in hypothyroidism. *J Clin Endocrinol Metab*. 2006;91(12):4930-4937.
61. Kushchayeva YS, Startzell M, Cochran E, Auh S, Sekizkardes H, Soldin SJ, Kushchayev SV, Dieckmann W, Skarulis M, Abdul Sater Z, Brychta RJ, Cypess AM, Lin TC, Lightbourne M, Millo C, Brown RJ. Thyroid Hormone Effects on Glucose Disposal in Patients With Insulin Receptor Mutations. *J Clin Endocrinol Metab*. 2020;105(3):e158-171.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

62. Jun JE, Jee JH, Bae JC, Jin SM, Hur KY, Lee MK, Kim TH, Kim SW, Kim JH. Association Between Changes in Thyroid Hormones and Incident Type 2 Diabetes: A Seven-Year Longitudinal Study. *Thyroid*. 2017;27(1):29-38.
63. Jun JE, Jin SM, Jee JH, Bae JC, Hur KY, Lee MK, Kim SW, Kim JH. TSH increment and the risk of incident type 2 diabetes mellitus in euthyroid subjects. *Endocrine*. 2017;55(3):944-953.
64. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*. 2002;87(2):489-499.
65. Waise A, Price HC. The upper limit of the reference range for thyroid-stimulating hormone should not be confused with a cut-off to define subclinical hypothyroidism. *Ann Clin Biochem*. 2009;46(Pt 2):93-98.
66. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. *J Clin Endocrinol Metab*. 2005;90(9):5483-5488.
67. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM, American Thyroid Association Task Force on Thyroid Hormone R. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. *Thyroid*. 2014;24(12):1670-1751.
68. Niranjana U, Wright NP. Should we treat subclinical hypothyroidism in obese children? *Bmj*. 2016;352:i941.
69. Gunapalasingham G, Frithioff-Bojsoe C, Lund MAV, Hedley PL, Fonvig CE, Dahl M, Pedersen O, Christiansen M, Hansen T, Lausten-Thomsen U, Holm JC. Reference values for fasting serum concentrations of thyroid-stimulating hormone and thyroid hormones in healthy Danish/North-European white children and adolescents. *Scandinavian journal of clinical and laboratory investigation*. 2019;79(1-2):129-135.

Table 1. Demographic distribution of the cohort

	BMI < 85 %tile Median (95% CI)	BMI ≥ 85 %tile Estimate (95% CI)	p-value
Proportion of population, %	68.7 (65.9-71.5)	31.2 (28.5-34.1)	
Male, %	51.3 (48.8-53.8)	52.2 (48.1- 56.2)	.73
Age, mean (years)	15.3 (15.2-15.5)	15.2 (14.9-15.4)	.28
Race/ethnicity, %			
Hispanic	15.7 (12.8-19.3)	22.9 (18.1-28.6)	.001
Non-Hispanic Black	12.7 (10.6-15.1)	20.2 (16.3-24.7)	<.001
Non-Hispanic White	63.0 (59.1-66.8)	50.5 (44.3-56.7)	<.001
BMI z-score	0.07 (0.02-0.13)	1.76 (1.71-1.80)	<.001
Waist circumference z-score	-0.05 (-0.02-0.08)	1.42 (1.37-1.46)	<.001
Abdominal obesity, %	6.6 (5.1-8.7)	92.9 (90.8-94.5)	<.001
Waist-height ratio > 0.5, %	12.3 (9.2-16.3)	93.0 (90.8-94.7)	<.001
Systolic BP, mm Hg	107.0 (106.5-107.5)	112.0 (111.0-113.0)	<.001
TSH (uIU/mL)	1.33 (1.28-1.39)	1.49 (1.43-1.54)	<.001
Total T4 (ug/dL)	7.50 (7.45-7.55)	7.60 (7.50-7.70)	.07
Total T3 (ng/dL)	129.0 (127.0-131.0)	131.5 (129.0-133.9)	.12
Free T4 (ng/dL)	0.80 (0.78-0.81)	0.80 (0.77-0.81)	.31
Free T3 (pg/mL)	3.63 (3.60-3.65)	3.70 (3.65-3.75)	.009
Triglyceride (mg/dL)	66.0 (63.1-68.9)	83.0 (77.6-88.4)	<.001
HDL-cholesterol (mg/dL)	52.0 (51.0-53.0)	45.0 (44.0-46.0)	<.001
HOMA-IR	1.74 (1.66-1.81)	3.24 (3.01-3.46)	<.001
ALT (U/L)	15.0 (14.5-15.5)	19.0 (18.5-19.5)	<.001

Abbreviations: BMI = body mass index; BP= blood pressure; TSH= thyroid stimulating hormone; T4 = thyrotropin; T3= thyroxine; HDL = high density lipoprotein; HOMA-IR = homeostatic model for insulin resistance, ALT = alanine transferase
SI unit conversion: Total T4 (nmol/L) = multiply by 12.9; Total T3 (nmol/L) = multiply by 0.0154; fT4 (pmol/L) = multiply by 12.9; fT3 (pmol/L) = multiply by 1.5362; TG (mmol/L) = multiply by 0.0113; HDL-C (mmol/L) = multiply by 0.0259
^aBMI percentile adjusted for age and sex

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Table 2. Association between 4th quantile of TSH and cardiometabolic risk factors

Regression models	Subpopulation size (population represented)	Model 1		Model 2		Model 3	
		OR* (95% CI)	p-value	OR* (95% CI)	p-value	OR* (95% CI)	p-value
Abdominal obesity	2509 (13.6 million)	3.47 (2.37-5.10)	<.001	3.57 (2.42-5.25)	<.001	2.53 (1.43-4.46)	.002
Hypertriglyceridemia	1118 (12.1 million)	2.08 (1.01-4.27)	.04	2.12 (1.00-4.92)	.05	1.84 (0.84-4.00)	.12
Low HDL cholesterol	2548 (13.8 million)	1.03 (0.67-1.58)	.89	1.02 (0.66-1.58)	.92	0.81 (0.51-1.29)	.37
Elevated blood pressure	2199 (11.9 million)	1.74 (1.05-2.87)	.03	1.98 (1.21-3.23)	.007	1.65 (1.00-2.73)	.05
Hyperglycemia	1118 (12.1 million)	1.33 (0.73-2.41)	.35	1.15 (0.64-2.07)	.63	1.15 (0.62-2.11)	.65
HOMA-IR	1112 (12.0 million)	3.34 (1.91-5.85)	<.001	3.50 (1.98-6.17)	<.001	2.82 (1.42-5.57)	.003
Elevated ALT level	2546 (13.9 million)	1.65 (0.48-5.66)	.42	1.79 (0.54-5.95)	.97	1.02 (0.33-3.17)	.97
Risk score	1118 (12.1 million)	2.41 (1.42-4.07)	.001	2.30 (1.34-3.97)	.003	2.20 (1.23-3.95)	.009

Abbreviations: OR = odds ratio, HDL = high-density lipoprotein, HOMA-IR = homeostatic model for insulin resistance, ALT = alanine transferase
TSH quantile defined by quantile regression model adjusted for age and sex. 1st Quantile used as reference.

Model 1= unadjusted; Model 2= adjusted for age, sex and race/ethnicity; Model 3 = adjusted for age, sex, race/ethnicity and BMI

Table 3. Age- and sex-specific percentiles for thyroid parameters

TSH level (μU/mL)

Age (years)	Percentiles for boys								Percentiles for girls							
	Sample size	2.5	5	25	50	75	95	97.5	Sample size	2.5	5	25	50	75	95	97.5
12	111	0.5	0.6	1.1	1.6	2.2	3.6	4.3	106	0.4	0.5	1.0	1.4	2.1	3.8	4.8
13	132	0.5	0.6	1.1	1.6	2.2	3.6	4.3	150	0.4	0.5	0.9	1.4	2.0	3.7	4.6
14	135	0.5	0.6	1.1	1.5	2.2	3.6	4.2	158	0.4	0.5	0.9	1.3	1.9	3.5	4.4
15	142	0.4	0.6	1.0	1.4	2.0	3.3	4.0	122	0.4	0.5	0.9	1.3	1.8	3.4	4.2
16	143	0.4	0.5	1.0	1.4	1.9	3.1	3.7	132	0.4	0.5	0.8	1.2	1.8	3.2	4.1
17	131	0.4	0.5	0.9	1.4	1.9	3.1	3.7	123	0.4	0.4	0.8	1.1	1.7	3.1	3.9
18	100	0.4	0.5	1.0	1.4	2.0	3.2	3.9	109	0.3	0.4	0.8	1.1	1.6	3.0	3.7

Total T4 level (μg/dL)

Age (years)	Percentiles for boys								Percentiles for girls							
	Sample size	2.5	5	25	50	75	95	97.5	Sample size	2.5	5	25	50	75	95	97.5
12	92	5.3	5.6	6.6	7.4	8.3	9.8	10.0	81	5.3	5.6	6.8	7.6	8.5	10.0	11.0
13	115	5.2	5.5	6.5	7.2	8.1	9.6	10.0	114	5.3	5.6	6.7	7.5	8.4	10.0	11.0
14	113	5.1	5.4	6.4	7.1	7.9	9.4	10.0	130	5.3	5.6	6.7	7.5	8.4	10.0	11.0
15	113	5.1	5.4	6.4	7.1	8.0	9.4	10.0	98	5.3	5.7	6.8	7.6	8.5	10.0	11.0
16	122	5.1	5.5	6.4	7.2	8.1	9.5	10.0	112	5.4	5.8	6.9	7.7	8.7	10.0	11.0
17	114	5.2	5.5	6.5	7.3	8.2	9.7	10.0	100	5.5	5.9	7.1	7.9	8.8	11.0	11.0
18	89	5.3	5.6	6.6	7.4	8.3	9.8	10.0	94	5.7	6.0	7.2	8.1	9.0	11.0	12.0

Total T3 level (ng/dL)

Age (years)	Percentiles for boys								Percentiles for girls							
	Sample size	2.5	5	25	50	75	95	97.5	Sample size	2.5	5	25	50	75	95	97.5
12	61	112	118	137	151	166	191	200	65	99	105	125	138	154	185	197
13	91	108	114	132	146	160	184	193	89	91	97	115	128	142	171	182
14	87	104	110	128	141	154	178	186	96	87	93	110	122	136	163	175
15	93	100	105	123	135	149	171	179	76	85	91	108	120	133	159	170
16	91	96	101	118	130	143	164	172	84	85	90	107	118	132	158	169
17	91	92	97	113	125	137	158	165	79	85	91	108	120	133	159	170
18	72	88	93	108	119	131	151	158	69	88	94	111	124	137	165	176

Free T4 level (ng/dL)

Age (years)	Percentiles for boys								Percentiles for girls							
	Sample size	2.5	5	25	50	75	95	97.5	Sample size	2.5	5	25	50	75	95	97.5
12	61	0.6	0.6	0.7	0.8	0.9	1.0	1.1	65	0.6	0.6	0.7	0.8	0.9	1.0	1.1
13	91	0.6	0.6	0.7	0.8	0.9	1.0	1.1	89	0.6	0.6	0.7	0.8	0.9	1.0	1.1
14	87	0.6	0.6	0.7	0.8	0.9	1.0	1.1	97	0.6	0.6	0.7	0.8	0.9	1.0	1.1
15	93	0.6	0.6	0.7	0.8	0.9	1.0	1.1	76	0.6	0.6	0.7	0.8	0.9	1.0	1.1

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

16	91	0.6	0.6	0.7	0.8	0.9	1.0	1.1	84	0.6	0.6	0.7	0.8	0.9	1.0	1.1
17	91	0.6	0.6	0.7	0.8	0.9	1.0	1.1	79	0.6	0.6	0.7	0.8	0.9	1.0	1.1
18	72	0.6	0.6	0.7	0.8	0.9	1.0	1.1	69	0.6	0.6	0.7	0.8	0.9	1.0	1.1

Free T3 level (pg/mL)																
Age (years)	Percentiles for boys								Percentiles for girls							
	Sample size	2.5	5	25	50	75	95	97.5	Sample size	2.5	5	25	50	75	95	97.5
12	61	3.3	3.4	3.8	4.0	4.3	4.8	5.0	65	3.1	3.2	3.5	3.8	4.0	4.5	4.7
13	91	3.2	3.4	3.7	3.9	4.2	4.7	4.9	89	3.0	3.1	3.4	3.6	3.8	4.3	4.5
14	87	3.2	3.3	3.6	3.8	4.1	4.6	4.8	96	2.9	3.0	3.3	3.5	3.7	4.2	4.4
15	93	3.1	3.2	3.5	3.7	4.0	4.4	4.6	76	2.8	2.9	3.2	3.4	3.6	4.1	4.3
16	91	3.0	3.1	3.4	3.7	3.9	4.3	4.5	84	2.7	2.8	3.1	3.3	3.5	4.0	4.2
17	91	3.0	3.1	3.4	3.6	3.8	4.2	4.4	78	2.7	2.8	3.1	3.3	3.5	4.0	4.2
18	72	2.9	3.0	3.3	3.5	3.7	4.1	4.3	69	2.8	2.9	3.2	3.4	3.6	4.1	4.3

Abbreviations: TSH= thyroid stimulating hormone; T4 = thyrotropin; T3= thyroxine

SI units conversion: Total T4 (nmol/L) = multiply by 12.9; Total T3 (nmol/L) = multiply by 0.0154; fT4 (pmol/L) = multiply by 12.9; fT3 (pmol/L) = multiply by 1.5362

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Figure 1. Proportion of subjects in each quantile of TSH based on the BMI percentile